Regencell Bioscience (NASDAQ:RGC) Stock Price Up 0.8% – Should You Buy?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price was up 0.8% during trading on Wednesday . The company traded as high as $5.35 and last traded at $5.06. Approximately 186,837 shares were traded during trading, a decline of 20% from the average session volume of 232,156 shares. The stock had previously closed at $5.02.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on RGC shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. Wall Street Zen cut shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The firm has a 50-day simple moving average of $8.67 and a two-hundred day simple moving average of $20.73.

Institutional Trading of Regencell Bioscience

Hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC purchased a new position in Regencell Bioscience during the second quarter valued at approximately $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience in the second quarter valued at approximately $768,000. XTX Topco Ltd purchased a new stake in Regencell Bioscience in the 3rd quarter worth approximately $598,000. Hudson Bay Capital Management LP purchased a new stake in Regencell Bioscience in the 4th quarter worth approximately $275,000. Finally, Vident Advisory LLC boosted its position in Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after purchasing an additional 11,866 shares in the last quarter. Hedge funds and other institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.